
## Fei Yang

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1802932/publications.pdf Version: 2024-02-01



FEL YANG

| #  | Article  | IF   | CITATIONS |
|----|--|------|-----------|
| 1  | Effector memory cytotoxic CD3+/CD8+/CD45RO+ T cells are predictive of good survival and a lower risk of recurrence in triple-negative breast cancer. Modern Pathology, 2022, 35, 601-608.  | 5.5  | 10        |
| 2  | Identification of biomarkers of response to preoperative talazoparib monotherapy in treatment naÃ <sup>-</sup> ve<br>gBRCA+ breast cancers. Npj Breast Cancer, 2022, 8, 64.  | 5.2  | 3         |
| 3  | Tumor Immune Microenvironment Changes by Multiplex Immunofluorescence Staining in a Pilot Study<br>of Neoadjuvant Talazoparib for Early-Stage Breast Cancer Patients with a Hereditary <i>BRCA</i><br>Mutation. Clinical Cancer Research, 2022, 28, 3669-3676. | 7.0  | 3         |
| 4  | TRPS1: a highly sensitive and specific marker for breast carcinoma, especially for triple-negative breast cancer. Modern Pathology, 2021, 34, 710-719.   | 5.5  | 90        |
| 5  | The clinical efficacy and safety of single-agent pembrolizumab in patients with recurrent granulosa<br>cell tumors of the ovary: a case series from a phase II basket trial. Investigational New Drugs, 2021, 39,<br>829-835.                                  | 2.6  | 8         |
| 6  | First in class dual MDM2/MDMX inhibitor ALRN-6924 enhances antitumor efficacy of chemotherapy in TP53 wild-type hormone receptor-positive breast cancer models. Breast Cancer Research, 2021, 23, 29.  | 5.0  | 31        |
| 7  | CD8+ T cells inhibit metastasis and CXCL4 regulates its function. British Journal of Cancer, 2021, 125, 176-189.   | 6.4  | 21        |
| 8  | A 95-gene signature stratifies recurrence risk of invasive disease in ER-positive, HER2-negative,<br>node-negative breast cancer with intermediate 21-gene signature recurrence scores. Breast Cancer<br>Research and Treatment, 2021, 189, 455-461.           | 2.5  | 6         |
| 9  | Immune Phenotype and Response to Neoadjuvant Therapy in Triple-Negative Breast Cancer. Clinical<br>Cancer Research, 2021, 27, 5365-5375.   | 7.0  | 29        |
| 10 | Sphingosine Kinase 1 Signaling Promotes Metastasis of Triple-Negative Breast Cancer. Cancer Research, 2019, 79, 4211-4226.   | 0.9  | 48        |
| 11 | Targeting the Interplay between Epithelial-to-Mesenchymal-Transition and the Immune System for Effective Immunotherapy. Cancers, 2019, 11, 714.  | 3.7  | 79        |
| 12 | The Immune Microenvironment in Hormone Receptor–Positive Breast Cancer Before and After<br>Preoperative Chemotherapy. Clinical Cancer Research, 2019, 25, 4644-4655.   | 7.0  | 76        |
| 13 | Atypical plant homeodomain of UBR7 functions as an H2BK120Ub ligase and breast tumor suppressor.<br>Nature Communications, 2019, 10, 1398.   | 12.8 | 35        |
| 14 | A functional genomic screen in vivo identifies CEACAM5 as a clinically relevant driver of breast cancer, 2018, 4, 9.   | 5.2  | 32        |
| 15 | Interobserver Agreement Between Pathologists Assessing Tumor-Infiltrating Lymphocytes (TILs) in<br>Breast Cancer Using Methodology Proposed by the International TILs Working Group. Annals of<br>Surgical Oncology, 2016, 23, 2242-2248.                      | 1.5  | 85        |
| 16 | Increased VEGFR-2 Gene Copy Is Associated with Chemoresistance and Shorter Survival in Patients<br>with Non–Small-Cell Lung Carcinoma Who Receive Adjuvant Chemotherapy. Cancer Research, 2011, 71,<br>5512-5521.  | 0.9  | 55        |